University Of Warmia And Mazury
- Address
- Al. Wojska Polskiego 35, 10-228 Olsztyn, Poland
University of Warmia and Mazury - Rare Rheumatologic Disease Research
The University of Warmia and Mazury conducts specialized research in rare rheumatologic and inflammatory conditions, with particular expertise in complex syndromes that affect both musculoskeletal and dermatological systems. The center focuses on evaluating advanced biologic therapies for conditions that significantly impact patient quality of life through chronic pain and functional limitations.
- SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) treatment and management
- Biologic therapy efficacy in rare inflammatory arthropathies
- Spondyloarthritis and axial skeletal involvement in systemic syndromes
The research center specializes in investigating etanercept and other TNF inhibitors for rare disease applications, conducting placebo-controlled trials in patients with complex presentations including arthritis, osteitis, and pustular psoriasis. Their work addresses critical unmet needs in conditions that can lead to severe complications such as bone destruction, particularly in the sternoclavicular region, while evaluating both efficacy and safety profiles in combination with conventional disease-modifying antirheumatic drugs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Warmia And Mazury
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Etanercept Versus Placebo in SAPHO Syndrome Patients Undergoing Standard NSAID and DMARD Therapy | Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher | Phase IV | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etanercept | 1 | Unknown | 2024-10-22 | 2024-10-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.